SOURCE: CLX Investment Company, Inc.

December 18, 2007 09:59 ET

CLX Investment Company Announces Preparations for Clinical Trials for Zonda's Rapid Point of Care Test for Chlamydia

Mid to Late 1st Quarter 2008 Targeted for Initiation of Clinical Trials

MURRIETA, CA--(Marketwire - December 18, 2007) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that Safis Solutions, LLC is preparing to initiate clinical trials for Zonda's rapid point of care test for Chlamydia as part of the process to achieve FDA clearance for the product. CLX anticipates a mid to late first calendar quarter 2008 beginning for the clinical trials for the Zonda Chlamydia product.

Safis Solutions (www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.

As part of the preparations for clinical trials, Safis has sent out bid requests to several Contract Research Organizations (CROs) to conduct the studies for Zonda, and CLX expects to have a contract in place with a CRO by the end of December.

Safis has initiated work on the testing protocol and will submit it to the FDA before testing begins. Safis has developed estimates on the number of expected clinical sites and the anticipated timeframe necessary to gather data. Once the clinical data is completed, the data will be analyzed and Safis Solutions will prepare and submit documents for FDA clearance, which will allow for its sale in the United States.

"We are pleased with the schedule that Safis Solutions has developed for clinical trials and subsequent work related to the planned FDA submission for Zonda's Chlamydia test," stated Vera Leonard, president and chief executive officer of CLX Investment Company. "The anticipated timetable for the FDA submission should compare very favorably with the standard expectations for the process. We look forward to initiating the clinical trials under the guidance of Safis Solutions and AHP, and we plan to keep CLX shareholders updated with any reportable milestones in the process."

According to the "Centers for Disease Control and Prevention: 2006 Surveillance Data, Chlamydia" and the "U.S. Census Bureau, 2006 population estimates," Chlamydia trachomatis infections are the most commonly reported notifiable disease in the United States. They are among the most prevalent of all STDs and, since 1994, have comprised the largest proportion of all STDs reported to CDC.

In women, chlamydial infections, which are usually asymptomatic, may result in pelvic inflammatory disease (PID), which is a major cause of infertility, ectopic pregnancy, and chronic pelvic pain. As with other inflammatory STDs, chlamydial infection can facilitate the transmission of HIV infection. In addition, pregnant women infected with Chlamydia can pass the infection to their infants during delivery, potentially resulting in neonatal ophthalmia and pneumonia. Due to the large burden of disease and risks associated with infection, CDC recommends screening all sexually active women younger than 26 years of age for Chlamydia annually.

According to the estimates from the U.S. Census Department, in July 2006 there were 42,435,426 females between the ages of 15 years and 24 years of age. In 2006, 1,030,911 chlamydial infections were reported to CDC from 50 states and the District of Columbia. This is the first time in history that reported cases of Chlamydia in the U.S. have exceeded 1 million.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. Information regarding Zonda can be found on its official website, www.zondaincusa.com. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-677-8073
    Email Contact